Neoplasms

Digestive System Diseases

All Conditions

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Capecitabine

Irinotecan

Cetuximab

Antimetabolites

Topoisomerase I Inhibitors

Enzyme Inhibitors

Antineoplastic Agents, Immunological

Cetuximab, Irinotecan, Capecitabine

Kyung Hae Jung, M.D.Ph.D

This study is to estimate the pathologic complete response rate of cetuximab, irinotecan, and capecitabine concurrent with radiotherapy given preoperatively in patients with resectable rectal cancer.

Daily fractions of radiotherapy at 1.8 Gy to total of 45 Gy to tumor and draining lymph nodes and followed by a coned-down boost of 5.4 Gy to the tumor are delivered concurrently with chemotherapy.

Cetuximab 400 mg/m2 is given intravenously on D-6 (1 week before radiation), followed by 250 mg/m2 once a week (D 1, 8, 15, 22 \& 29).

Administration of irinotecan and capecitabine starts on day 1 of radiotherapy. Capecitabine is administered orally at a dose of 825 mg/m2 twice daily during weekdays (Monday to Friday) during radiotherapy. Irinotecan 40 mg/m2 is given intravenously once a week (D 1, 8, 15, 22 \& 29).

Four to eight weeks after completion of chemoradiotherapy, curative surgery is performed.

Safety evaluation of the study will be performed after the first 6 patients treated. If more than 1 out of 6 patients received less than 70-80% of planned dose of capecitabine or irinotecan, the dosage of chemotherapy in the further study patients will be adjusted by a protocol amendment.

Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer

A Phase II Study of Pre-Operative Concurrent Chemoradiotherapy With Cetuximab, Irinotecan, and Capecitabine in Resectable Rectal Cancer

National Cancer Center, Korea

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer	NCT00506844	Rectal Neoplasm... Neoadjuvant Tre...	Cetuximab, Irin...	18 Years - 75 Years	National Cancer Center, Korea
Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer	NCT00506844	Rectal Neoplasm... Neoadjuvant Tre...	Cetuximab, Irin...	18 Years - 75 Years	National Cancer Center, Korea

Spots Global Cancer Trial Database for cetuximab, irinotecan, capecitabine